Imugene Ltd (ASX:IMU) is a clinical-stage immuno-oncology company that has transitioned from a wide-ranging pipeline into a highly-focused vehicle concentrating on CAR-T. It is currently developing its platform azer-cel, an allogeneic ‘off-the-shelf’ CD19 CAR-T cell therapy for blood cancers. Since our Initiation Report on 11 May 2026, IMU has issued several ASX announcements that we summarise in this report. Of note is further progress and updated data on the company’s Phase 1b trial, and azer-cel being granted FDA Fast Track Designation in two blood cancer indications [Chronic Lymphocytic Leukaemia / Small Lymphocytic Lymphoma (CLL/SLL) and relapsed or refractory Marginal Zone Lymphoma (MZL)]. The updated clinical trial data continues to be incrementally positive, and we anticipate that the company will continue to provide a steady flow of updates over the coming months as it progresses its Phase 1b trial. Our probability-weighted NPV (rNPV) for IMU remains at $0.24/share.
